Previous 10 | Next 10 |
2024-05-07 10:01:47 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
2024-05-06 13:17:53 ET More on Mid-day movers & stocks. Manitex International, Inc. 2024 Q1 - Results - Earnings Call Presentation Manitex International, Inc. (MNTX) Q1 2024 Earnings Call Transcript Manitex International, Inc. (MNTX) Q4 2023 Earnings Call Transcr...
2024-05-06 10:01:41 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says...
2024-05-02 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors should keep their eyes on the global nanotechnology market , which was valued at USD 3.78 billion in 2022 and is expected to reach USD 74.1 billion by 2032, growing at a CAGR of 3...
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, ...
2024-02-15 06:38:29 ET More on NanoViricides Seeking Alpha’s Quant Rating on NanoViricides Historical earnings data for NanoViricides Financial information for NanoViricides Read the full article on Seeking Alpha For further details see: Na...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 o...
2024-01-29 12:52:58 ET More on NanoViricides Seeking Alpha’s Quant Rating on NanoViricides Historical earnings data for NanoViricides Financial information for NanoViricides Read the full article on Seeking Alpha For further details see: Na...
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory viral infe...
SHELTON, CT / ACCESSWIRE / July 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutioni...
--News Direct-- NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share promising news about the company's ultra-broad-spectrum antiviral, NV-387. The antiviral was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse mod...